Trials / Terminated
TerminatedNCT02494778
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 248 (actual)
- Sponsor
- Prilenia · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pridopidine | 45 mg BID |
Timeline
- Start date
- 2015-09-24
- Primary completion
- 2018-01-12
- Completion
- 2018-01-12
- First posted
- 2015-07-10
- Last updated
- 2021-09-17
- Results posted
- 2021-09-17
Locations
46 sites across 11 countries: United States, Australia, Austria, Canada, France, Germany, Italy, Netherlands, Poland, Russia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02494778. Inclusion in this directory is not an endorsement.